Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 17/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 15/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 14/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 13/20 | 0.71 |
| ▸ | HDAC7 | Q8WUI4 | 13/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 0.71 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 0.71 |
| ▸ | HDAC9 | Q9UKV0 | 13/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 13/20 | 0.71 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.59 |
| ▸ | EP300 | Q09472 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502203 | 1.00 | HDAC1 (0.71) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL8119450 | 0.89 | HDAC6 (0.76) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL8113232 | 0.89 | HDAC6 (0.76) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL8117831 | 0.88 | HDAC6 (0.77) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL8061147 | 0.88 | HDAC1 (0.75) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL3504520 | 0.86 | HDAC1 (0.64) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL3504524 | 0.86 | HDAC1 (0.64) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL14345915 | 0.86 | HDAC6 (0.72) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL13288533 | 0.85 | HDAC1 (0.65) | HDAC1HDAC4HDAC2HDAC6HDAC3 | |
| SCHEMBL8068180 | 0.85 | HDAC6 (0.75) | HDAC1HDAC4HDAC2HDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795304-B2 | such as S)-[6-Hydroxycarbamoyl-1-(4-phenyl-thiazol-2-ylcarbamoyl)-hexyl]-carbamic acid benzyl ester, useful in the prevention and/or treatment cancer, restenosis, autoimmune diseases, allergies, inflammatory diseases, nervous system disorders such as neurodegenerative diseases | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | claimed |
| US-20090118291-A1 | Histone deacetylase inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | claimed |
| EP-1784194-A1 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | claimed |
| WO-2006026260-A1 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-03-09 | — | — | WO | claimed |
| US-7795304-B2 | such as S)-[6-Hydroxycarbamoyl-1-(4-phenyl-thiazol-2-ylcarbamoyl)-hexyl]-carbamic acid benzyl ester, useful in the prevention and/or treatment cancer, restenosis, autoimmune diseases, allergies, inflammatory diseases, nervous system disorders such as neurodegenerative diseases | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795304-B2 | such as S)-[6-Hydroxycarbamoyl-1-(4-phenyl-thiazol-2-ylcarbamoyl)-hexyl]-carbamic acid benzyl ester, useful in the prevention and/or treatment cancer, restenosis, autoimmune diseases, allergies, inflammatory diseases, nervous system disorders such as neurodegenerative diseases | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795304-B2 | such as S)-[6-Hydroxycarbamoyl-1-(4-phenyl-thiazol-2-ylcarbamoyl)-hexyl]-carbamic acid benzyl ester, useful in the prevention and/or treatment cancer, restenosis, autoimmune diseases, allergies, inflammatory diseases, nervous system disorders such as neurodegenerative diseases | MERCK SHARP & DOHME CORP. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090118291-A1 | Histone deacetylase inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118291-A1 | Histone deacetylase inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| US-20090118291-A1 | Histone deacetylase inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
| EP-1784194-A1 | HISTONE DEACETYLASE INHIBITORS | Merck & Co., Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006026260-A1 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006026260-A1 | HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118291-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC9 | HDAC1 1/4885HDAC4 5/4885HDAC2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.